Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II.
Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II.
复制标题
DOI：
10.1155/2017/2520581
复制
发表时间：
2017
影响因子：
2
通讯作者：
Hu L
中科院分区：
文献类型：
--
作者：
Wang Y;Wu Z;Hu L
我们的目的是探讨二甲双胍治疗与上皮间质转化（EMT）表型之间的关联，并进一步评估二甲双胍和EMT标志物E-钙粘蛋白和波形蛋白在临床实践中对结直肠癌（CRC）的预后价值。 我们收集了 102 名预诊断为 2 型糖尿病 (DM II) 的 I 至 III 期 CRC 患者的标本并评估了临床病理参数。采用免疫组织化学（IHC）检测肿瘤中E-cadherin和vimentin的表达，并使用SPSS 19.0进行统计分析。 在相关性检验中，我们发现使用二甲双胍的患者肿瘤细胞EMT程度较低（E-cadherin（P = 0.014）和波形蛋白（Vimentin）表达较少（P = 0.011），且E-cadherin和vimentin的表达与血清CA19-9（P = 0.048，P = 0.009）、肿瘤浸润深度（T）（P < 0.001，P =在 Cox 多变量回归分析中，E-钙粘蛋白被确定为无病生存 (DFS) (P = 0.038) 和二甲双胍使用 (P = 0.015P = 0.044) 和淋巴侵袭 (P = 0.016P = 0.045) 和淋巴侵袭 (P = 0.016P = 0.044) 的预后因素。 0.023）被认为是 DFS 和总生存期 (OS) 的预后因素，我们的研究表明二甲双胍可能会阻碍 EMT 过程并提高 I-III 期 CRC 合并 DM II 患者的生存率。
We aimed to explore the association between metformin treatment and epithelial-mesenchymal transition (EMT) phenotype and further appraise the prognostic values of metformin and EMT markers E-cadherin and vimentin for colorectal cancer (CRC) in clinical practice. We collected specimens and evaluated clinicopathological parameters of 102 stage I to III CRC patients with prediagnosed type 2 diabetes mellitus (DM II). Expression of E-cadherin and vimentin in tumors was detected by immunohistochemistry (IHC), and statistical analysis was performed using SPSS 19.0. In correlation tests, we found a lower tumor cell EMT degree (more E-cadherin (P = 0.014) and less vimentin (P = 0.011) expression in patients who used metformin, and the expression of E-cadherin and vimentin was associated with serum CA19-9 (P = 0.048, P = 0.009), tumor invasive depth (T) (P < 0.001, P = 0.045), and lymph invasion (N) (P = 0.013, P = 0.001). In Cox multivariate regression analysis, E-cadherin was identified as a prognostic factor for disease-free survival (DFS) (P = 0.038) and metformin use (P = 0.015P = 0.044) and lymph invasion (P = 0.016P = 0.023) were considered as the prognostic factors for both DFS and overall survival (OS). Our study suggested that metformin may impede the EMT process and improve survival for stage I–III CRC patients with DM II.
登录
查看更多内容
影响因子：
6.4
作者：
Lee, Jin Ha;Kim, Tae Il;Kim, Won Ho
通讯作者：
Kim, Won Ho
影响因子：
2.5
作者：
Liu, Tong;Zhang, Xianyu;Pang, Da
通讯作者：
Pang, Da
影响因子：
--
作者：
Han, Baiyu;Cui, Hanzhi;Fan, Zhongyi
通讯作者：
Fan, Zhongyi
影响因子：
11.2
作者：
Li Y;Cao H;Jiao Z;Pakala SB;Sirigiri DN;Li W;Kumar R;Mishra L
通讯作者：
Mishra L
影响因子：
5.7
作者：
Cerezo, Michael;Tichet, Melanie;Rocchi, Stephane
通讯作者：
Rocchi, Stephane